Syndax (SNDX) announced positive topline results from the relapsed or refractory mutant NPM1 – mNPM1 – acute myeloid leukemia ...

Thanks to Joanna from Poland, I have no measurable leukemia. Getting college-age kids to join the bone-marrow donor registry ...

Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European Hematology Association Congress and received FDA guidance for a future ...

She had been treated for acute myeloid leukemia once before, but the fast-growing blood cancer came back. A bone marrow ...

" I’m honored to join Innate Pharma at such a pivotal moment in its evolution,”said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “ We achieved notable regul ...

The study is testing the drug in certain patients with relapsed or refractory acute myeloid leukemia (AML). The small ...

Designed to be orally available, tamibarotene is a selective agonist of the retinoic acid receptor alpha (RARA), which when overexpressed can prevent the differentiation of bone marrow cells into ...

Researchers at Kennedy Krieger Institute's International Center for Spinal Cord Injury (ICSCI) have made a remarkable ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

Syndax Pharmaceuticals' experimental drug revumenib achieved 23% complete remission in NPM1-mutated acute myeloid leukemia ...